Business
SANUWAVE Health Announces Successful Filing of Patent for Use of Shockwaves to Treat Respiratory Ailments, Including Viral Infections Such as COVID-19
Concept Submitted to National Science Foundation for Funding Grant SUWANEE, GA, April 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc.
About this update from Sanuwave Health, Inc.
[{"type":"text","content":"\n Concept Submitted to National Science Foundation for Funding Grant SUWANEE, GA, April 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) announced today the successful filing of a patent for use of shockwaves to treat respiratory ailments including viral infections such as COVID-19, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Idiopathic Pulmonary Fibrosis (IPF), Pneumonia and Bronchitis. SANUWAVE has also submitted a grant proposal to the NSF (National Science Foundation) for Phase 1 funding to explore clinical research in the area of respiratory ailments, specifically on the treatment of COVID-19 and its debilitating health effects. The research on this subject will be done in partnership with fellow researchers at Montana State University’s Center for Biofilm Engineering. Commenting on the patent filings, Kevin A. Richardson II, Chairman of the Board and CEO of SANUWAVE, said, \"Every healthcare company in the US is working diligently to help solve and treat the COVID-19 pandemic. SANUWAVE’s team consulted with our clinical and science advisors and determined we could use our energy-based proprietary technology to help clear the lungs of mucus and/or change the viscosity of mucus, therefore, easing the constriction of the respiratory system from the mucus build up due to COVID-19. The treatment would be similar to percussion therapy currently being used but would use shockwave as a mechanism of action, which can allow for more focus and power when necessary. We had been exploring use of our technology to treat other respiratory ailments for quite some time, but with this crisis in the forefront, we are accelerating our research to help treat patients.\" Iulian Cioanta, Ph.D., Chief Science and Technology Officer of SANUWAVE Health, added, “With over 82 patents and patents pending in our portfolio, SANUWAVE has one of the most extensive IP-portfolios in the shockwave industry. Our team has been exploring respiratory ailment treatment for quite some time. We know from previously published clinical work that our technology produces a modulation of inflammation, to reduce the detrimental immune system overreaction, and at the same time increases vascularization. This should aid in the healing, lessen the pain in the patients suffering from COVID-19, and ultimately reduce scar...